197 related articles for article (PubMed ID: 35693625)
1. The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis.
Wang M; Zhang Y; Wang Z; Liu D; Mao S; Liang B
J Thorac Dis; 2022 May; 14(5):1620-1637. PubMed ID: 35693625
[TBL] [Abstract][Full Text] [Related]
2. Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials.
Sfairopoulos D; Liu T; Zhang N; Tse G; Bazoukis G; Letsas K; Goudis C; Milionis H; Vrettos A; Korantzopoulos P
Heart Fail Rev; 2023 Jul; 28(4):925-936. PubMed ID: 36282460
[TBL] [Abstract][Full Text] [Related]
3. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
[TBL] [Abstract][Full Text] [Related]
4. Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.
Li D; Liu Y; Hidru TH; Yang X; Wang Y; Chen C; Li KHC; Tang Y; Wei Y; Tse G; Xia Y
Front Endocrinol (Lausanne); 2021; 12():619586. PubMed ID: 33815278
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
Li WJ; Chen XQ; Xu LL; Li YQ; Luo BH
Cardiovasc Diabetol; 2020 Aug; 19(1):130. PubMed ID: 32847602
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
7. Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Yin Z; Zheng H; Guo Z
Front Cardiovasc Med; 2022; 9():902923. PubMed ID: 35665272
[TBL] [Abstract][Full Text] [Related]
8. Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death).
Liao J; Ebrahimi R; Ling Z; Meyer C; Martinek M; Sommer P; Futyma P; Di Vece D; Schratter A; Acou WJ; Zhu L; Kiuchi MG; Liu S; Yin Y; Pürerfellner H; Templin C; Chen S
Cardiovasc Diabetol; 2024 Feb; 23(1):78. PubMed ID: 38402177
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review.
Ouyang X; Wang J; Chen Q; Peng L; Li S; Tang X
Cardiovasc Diabetol; 2023 May; 22(1):124. PubMed ID: 37226247
[TBL] [Abstract][Full Text] [Related]
10. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; de Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI;
Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis.
Li C; Yu J; Hockham C; Perkovic V; Neuen BL; Badve SV; Houston L; Lee VYJ; Barraclough JY; Fletcher RA; Mahaffey KW; Heerspink HJL; Cannon CP; Neal B; Arnott C
Diabetes Obes Metab; 2022 Oct; 24(10):1927-1938. PubMed ID: 35589614
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis.
Shi W; Zhang W; Zhang D; Ren G; Wang P; Gao L; Chen H; Ding C
Heart Rhythm; 2021 Jul; 18(7):1090-1096. PubMed ID: 33684547
[TBL] [Abstract][Full Text] [Related]
14. Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials.
Zheng S; Lai Y; Jiang C; He L; Zhao Z; Li W; Tang R; Sang C; Long D; Du X; Ma C; Dong J
Pacing Clin Electrophysiol; 2024 Jan; 47(1):58-65. PubMed ID: 38010824
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in heart failure patients with and without atrial fibrillation receiving sodium-glucose cotransporter-2 inhibitor.
Hu WS; Lin CL
Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1977-1986. PubMed ID: 36881169
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic Atrial Fibrillation Ablation in Atrial Flutter Patients without Atrial Fibrillation: A Meta-Analysis with Trial Sequential Analysis.
Xie X; Liu X; Chen B; Wang Q
Med Sci Monit Basic Res; 2018 Jun; 24():96-102. PubMed ID: 29959310
[TBL] [Abstract][Full Text] [Related]
17. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists.
Scheen AJ
Diabetes Metab; 2022 Nov; 48(6):101390. PubMed ID: 36170946
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter.
Ahmari SA; Bunch TJ; Chandra A; Chandra V; Ujino K; Daly RC; Kushwaha SS; Edwards BS; Maalouf YF; Seward JB; McGregor CG; Chandrasekaran K
J Heart Lung Transplant; 2006 Jan; 25(1):53-60. PubMed ID: 16399531
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19: A systematic review and meta-analysis.
Szarpak L; Filipiak KJ; Skwarek A; Pruc M; Rahnama M; Denegri A; Jachowicz M; Dawidowska M; Gasecka A; Jaguszewski MJ; Iskrzycki L; Rafique Z
Cardiol J; 2022; 29(1):33-43. PubMed ID: 34897631
[TBL] [Abstract][Full Text] [Related]
20. Atrial fibrillation inducibility during cavotricuspid isthmus-dependent atrial flutter ablation as a predictor of clinical atrial fibrillation. A meta-analysis.
Romero J; Diaz JC; Di Biase L; Kumar S; Briceno D; Tedrow UB; Valencia CR; Baldinger SH; Koplan B; Epstein LM; John R; Michaud GF; Stevenson WG
J Interv Card Electrophysiol; 2017 Apr; 48(3):307-315. PubMed ID: 28070875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
